| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
calcium-sensing receptors[1]
Calcium-sensing receptor (CaSR). Upacicalcet acts as a CaSR agonist, binding to and activating the receptor on parathyroid cells, which suppresses parathyroid hormone (PTH) secretion. |
|---|---|
| ln Vitro |
Upacicalcet sodium is a CaSR agonist with an EC50 of 10.8 nM in cell-based assays. This potency underlies its ability to inhibit PTH secretion from parathyroid cells, leading to reduced serum iPTH and calcium levels both in vitro and in vivo.
|
| ln Vivo |
In an adenine-induced secondary hyperparathyroidism (SHPT) rat model, Upacicalcet sodium improves vascular calcification and bone disorders. It also inhibits cortical bone pore formation and reduces bone fibrosis in rats with chronic kidney disease (CKD), demonstrating therapeutic benefits beyond simple PTH suppression.
|
| Enzyme Assay |
A cell-free CaSR activation assay is challenging due to its GPCR nature requiring cellular context. However, GTPgammaS binding assays using membranes from CaSR-expressing cells can measure receptor activation. Membranes are incubated with [35S]GTPgammaS and various agonist concentrations; bound radioactivity is quantified to determine the EC50, reflecting G-protein activation by the agonist.
|
| Cell Assay |
HEK293 cells stably expressing human CaSR are seeded in 96-well plates and loaded with a calcium-sensitive fluorescent dye. Cells are treated with varying concentrations of Upacicalcet sodium. The resulting increase in intracellular calcium flux, measured as a change in fluorescence intensity, is used to calculate the EC50 (10.8 nM) for receptor activation.
|
| Animal Protocol |
Upacicalcet is administered intravenously in animal models. In the adenine-induced SHPT rat model, efficacy is assessed by measuring serum iPTH, calcium, and phosphate levels at various time points post-dose. Histological analysis of bone and vascular tissues evaluates improvements in bone fibrosis and vascular calcification.
|
| ADME/Pharmacokinetics |
As a small molecule calcimimetic, Upacicalcet is administered intravenously, allowing for controlled and predictable pharmacokinetics. Studies show it effectively reduces serum iPTH levels in patients undergoing hemodialysis, and it has been approved in Japan for treating SHPT, demonstrating favorable PK properties for this indication.
|
| Toxicity/Toxicokinetics |
Long-term (52-week) clinical studies in Japanese hemodialysis patients have shown that Upacicalcet is well-tolerated and effective, improving serum phosphorus and corrected calcium control without inducing severe hypocalcemia. Common side effects include mild gastrointestinal issues and hypocalcemia, which are manageable.
|
| References | |
| Additional Infomation |
Upacicalcet sodium is a novel intravenous calcimimetic approved in Japan in June 2021 and launched in August 2021 for treating secondary hyperparathyroidism (SHPT) in hemodialysis patients. Compared to existing calcimimetics, it offers improved tolerability, a rapid onset of action, and reduced gastrointestinal side effects, while effectively maintaining long-term PTH and calcium-phosphate balance. It is currently being evaluated in long-term Phase 3 clinical trials.
|
| Molecular Formula |
C11H15CLN3NAO6S
|
|---|---|
| Molecular Weight |
375.76
|
| Exact Mass |
373.011
|
| CAS # |
2052969-18-1
|
| Related CAS # |
(Rac)-Upacicalcet;2649575-19-7;Upacicalcet;1333218-50-0
|
| PubChem CID |
141719047
|
| Appearance |
White to off-white solid powder
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
23
|
| Complexity |
528
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
N(C1C(=C(Cl)C=C(S([O-])(=O)=O)C=1)C)C(=O)NC[C@H](N)C(=O)O.[Na+]
|
| InChi Key |
KUQQRUUFBPFDOW-QRPNPIFTSA-M
|
| InChi Code |
InChI=1S/C11H14ClN3O6S.Na/c1-5-7(12)2-6(22(19,20)21)3-9(5)15-11(18)14-4-8(13)10(16)17;/h2-3,8H,4,13H2,1H3,(H,16,17)(H2,14,15,18)(H,19,20,21);/q;+1/p-1/t8-;/m0./s1
|
| Chemical Name |
sodium;3-[[(2S)-2-amino-2-carboxyethyl]carbamoylamino]-5-chloro-4-methylbenzenesulfonate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 100 mg/mL (267.56 mM)
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6613 mL | 13.3064 mL | 26.6127 mL | |
| 5 mM | 0.5323 mL | 2.6613 mL | 5.3225 mL | |
| 10 mM | 0.2661 mL | 1.3306 mL | 2.6613 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
